Mixed Kappa/Mu partial opioid agonists as potential treatments for cocaine dependence

Advances in Pharmacology

Volumn 69, Issue , 2014, Pages 387-418

  Bidlack, Jean M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Aminothiazolomorphinans; Antagonists; Antinociception; Buprenorphine; Butorphanol; CJ 15,208; Cocaine; GSK1521498; Inverse agonist; Nalbuphine; Nalmefene; Naltrexone; Partial agonists; Receptor binding

Indexed keywords

AMINOTHIAZOLOMORPHINAN; ARODYN; BUPRENORPHINE; BUTORPHAN; BUTORPHANOL; CJ 15208; CYCLAZOCINE; CYCLORPHAN; GSK 1521498; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MCL 420; MCL 741; METHADONE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALBUPHINE; NALMEFENE; NALTREXONE; OPIATE PEPTIDE; PENTAZOCINE; SAMIDORPHAN; UNCLASSIFIED DRUG; ZYKLOPHIN;

ALCOHOLISM; ARTICLE; BINDING AFFINITY; BINDING ASSAY; COCAINE DEPENDENCE; HUMAN; IN VITRO STUDY; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY;

AMINOTHIAZOLOMORPHINANS; ANTAGONISTS; ANTINOCICEPTION; BUPRENORPHINE; BUTORPHANOL; CJ-15,208; COCAINE; GSK1521498; INVERSE AGONIST; NALBUPHINE; NALMEFENE; NALTREXONE; PARTIAL AGONISTS; RECEPTOR BINDING; [(35)S]GTPΓS BINDING;

ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; COCAINE-RELATED DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHADONE; PEPTIDES, CYCLIC; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84893168612     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-420118-7.00010-X     Document Type: Chapter

References (136)

1. Aldrich J.V., McLaughlin J.P. Peptide kappa opioid receptor ligands: Potential for drug development. The AAPS Journal 2009, 11(2):312-322. 10.1208/s12248-009-9105-4.
2. Aldrich J.V., Patkar K.A., McLaughlin J.P. Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(43):18396-18401. 10.1073/pnas.0910180106.
3. Anastasio N.C., Stutz S.J., Fox R.G., Sears R.M., Emeson R.B., Dileone R.J., et al. Functional status of the serotonin 5-ht2c receptor (5-ht2cr) drives interlocked phenotypes that precipitate relapse-like behaviors in cocaine dependence. Neuropsychopharmacology 2013, 39:370-382. 10.1038/npp.2013.199.
4. Archer S., Albertson N.F., Harris L.S., Pierson A.K., Bird J.G. Pentazocine. Strong analgesics and analgesic antagonists in the benzomorphan series. Journal of Medicinal Chemistry 1964, 7:123-127.
5. Archer S., Glick S.D., Bidlack J.M. Cyclazocine revisited. Neurochemical Research 1996, 21(11):1369-1373. 10.1007/bf02532378.
6. Bart G., Schluger J.H., Borg L., Ho A., Bidlack J.M., Kreek M.J. Nalmefene induced elevation in serum prolactin in normal human volunteers: Partial kappa opioid agonist activity?. Neuropsychopharmacology 2005, 30(12):2254-2262. 10.1038/sj.npp.1300811.
7. Beardsley P.M., Howard J.L., Shelton K.L., Carroll F.I. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berlin) 2005, 183(1):118-126. 10.1007/s00213-005-0167-4.
8. 35S]GTP gamma S binding: A tool to evaluate functional activity of a cloned opioid receptor transiently expressed in COS cells. Neurochemical Research 1996, 21(11):1301-1307.
9. Bennett M.A., Murray T.F., Aldrich J.V. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist. Journal of Peptide Research 2005, 65(3):322-332. 10.1111/j.1399-3011.2005.00216.x.
10. Bidlack J.M., Cohen D.J., McLaughlin J.P., Lou R.L., Ye Y.C., Wentland M.P. 8-Carboxamidocyclazocine: A long-acting, novel benzomorphan. Journal of Pharmacology and Experimental Therapeutics 2002, 302(1):374-380. 10.1124/jpet.302.1.374.
11. Bidlack J.M., Knapp B.I. Mixed mu/kappa opioid agonists research and development of opioid-related ligands 2013, Vol. 1131:257-272. American Chemical Society, Washington, DC.
12. Bidlack J.M., McLaughlin J.P., Wentland M.P. Partial opioids. Medications for the treatment of pain and drug abuse. Annals of New York Academy of Sciences 2000, 909:1-11.
13. Bidlack J.M., Knapp B.I., Sromek A., Neumeyer J.L. A mixed kappa/mu partial opioid agonist attenuated cocaine-induced locomotion 2013, doi:. http://www.cpdd.vcu.edu/Pages/Meetings/CPDD13AbstractBook.pdf.
14. Burattini C., Burbassi S., Aicardi G., Cervo L. Effects of naltrexone on cocaine- and sucrose-seeking behaviour in response to associated stimuli in rats. International Journal of Neuropsychopharmacology 2008, 11(1):103-109. 10.1017/s1461145707007705.
15. Butelman E.R., Yuferov V., Kreek M.J. Kappa-opioid receptor/dynorphin system: Genetic and pharmacotherapeutic implications for addiction. Trends in Neurosciences 2012, 35(10):587-596. 10.1016/j.tins.2012.05.005.
16. Cambridge V.C., Ziauddeen H., Nathan P.J., Subramaniam N., Dodds C., Chamberlain S.R., et al. Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people. Biological Psychiatry 2013, 73(9):887-894. 10.1016/j.biopsych.2012.10.022.
17. Carey A.N., Borozny K., Aldrich J.V., McLaughlin J.P. Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn. European Journal of Pharmacology 2007, 569(1-2):84-89. 10.1016/j.ejphar.2007.05.007.
18. Ciccocioppo R., Economidou D., Rimondini R., Sommer W., Massi M., Heilig M. Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biological Psychiatry 2007, 61(1):4-12. 10.1016/j.biopsych.2006.01.006.
19. Comer S.D., Mogali S., Saccone P.A., Askalsky P., Martinez D., Walker E.A., et al. Effects of acute oral naltrexone on the subjective and physiological effects of oral d-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology 2013, 38:2427-2438. 10.1038/npp.2013.143.
20. Cordery S.F., Taverner A., Ridzwan I.E., Guy R.H., Delgado-Charro M.B., Husbands S.M., et al. A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm. Addiction Biology 2012, 10.1111/adb.12020.
21. Cowan A., Lewis J.W., Macfarlane I.R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. British Journal of Pharmacology 1977, 60(4):537-545.
22. Cunningham K.A., Anastasio N.C. Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. Neuropharmacology 2014, 10.1016/j.neuropharm.2013.06.030.
23. Cunningham K.A., Anastasio N.C., Fox R.G., Stutz S.J., Bubar M.J., Swinford S.E., et al. Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction. ACS Chemical Neuroscience 2013, 4(1):110-121. 10.1021/cn300072u.
24. Devroye C., Filip M., Przegalinski E., McCreary A.C., Spampinato U. Serotonin receptors and drug addiction: Focus on cocaine. Experimental Brain Research 2013, 230:537-545. 10.1007/s00221-013-3593-2.
25. Di Chiara G., Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. Journal of Pharmacology and Experimental Therapeutics 1988, 244(3):1067-1080.
26. Dole V.P., Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 1965, 193:646-650.
27. Dole V.P., Nyswander M.E., Kreek M.J. Narcotic blockade. Archives of Internal Medicine 1966, 118(4):304-309.
28. Downing J.W., Leary W.P., White E.S. Buprenorphine: A new potent long-acting synthetic analgesic. Comparison with morphine. British Journal of Anaesthesia 1977, 49(3):251-255.
29. Eans S.O., Ganno M.L., Reilley K.J., Patkar K.A., Senadheera S.N., Aldrich J.V., et al. The macrocyclic tetrapeptide [d-Trp]CJ-15,208 produces short-acting kappa opioid receptor antagonism in the CNS after oral administration. British Journal of Pharmacology 2013, 169(2):426-436. 10.1111/bph.12132.
30. Eap C.B., Buclin T., Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone-Implications for the treatment of opioid dependence. Clinical Pharmacokinetics 2002, 41(14):1153-1193. 10.2165/00003088-200241140-00003.
31. Evans C.J., Keith D.E., Morrison H., Magendzo K., Edwards R.H. Cloning of a delta opioid receptor by functional expression. Science 1992, 258(5090):1952-1955.
32. Freedman A.M., Fink M., Sharoff R., Zaks A. Cyclazocine and methadone in narcotic addiction. JAMA 1967, 202(3):191-194.
33. Fulton B.S., Knapp B.I., Bidlack J.M., Neumeyer J.L. Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors. Bioorganic & Medicinal Chemistry Letters 2008, 18(16):4474-4476. 10.1016/j.bmcl.2008.07.054.
34. Fulton B.S., Knapp B.L., Bidlack J.M., Neumeyer J.L. Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorganic & Medicinal Chemistry Letters 2010, 20(5):1507-1509. 10.1016/j.bmcl.2010.01.101.
35. Gates M. Cyclorphan and related compounds. Advances in Biochemical Psychopharmacology 1973, 8:51-56.
36. Gerra G., Fantoma A., Zaimovic A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. Journal of Psychopharmacology 2006, 20(6):806-814. 10.1177/0269881106060835.
37. Gerrits M.A., Kuzmin A.V., van Ree J.M. Reinstatement of cocaine-seeking behavior in rats is attenuated following repeated treatment with the opioid receptor antagonist naltrexone. European Neuropsychopharmacology 2005, 15(3):297-303. 10.1016/j.euroneuro.2004.11.004.
38. Giuliano C., Robbins T.W., Wille D.R., Bullmore E.T., Everitt B.J. Attenuation of cocaine and heroin seeking by mu-opioid receptor antagonism. Psychopharmacology 2013, 227(1):137-147. 10.1007/s00213-012-2949-9.
39. Goletiani N.V., Mendelson J.H., Sholar M.B., Siegel A.J., Mello N.K. Opioid and cocaine combined effect on cocaine-induced changes in HPA and HPG axes hormones in men. Pharmacology Biochemistry and Behavior 2009, 91(4):526-536. 10.1016/j.pbb.2008.09.007.
40. Greedy B.M., Bradbury F., Thomas M.P., Grivas K., Cami-Kobeci G., Archambeau A., et al. Orvinols with mixed kappa/mu opioid receptor agonist activity. Journal of Medicinal Chemistry 2013, 56(8):3207-3216. 10.1021/jm301543e.
41. Haggkvist J., Lindholm S., Franck J. The effect of naltrexone on amphetamine-induced conditioned place preference and locomotor behaviour in the rat. Addiction Biology 2009, 14(3):260-269. 10.1111/j.1369-1600.2009.00150.x.
42. Harris L.S., Pierson A.K. Some narcotic antagonists in the benzomorphan series. Journal of Pharmacology and Experimental Therapeutics 1964, 143:141-148.
43. Huang P., Kehner G.B., Cowan A., Liu-Chen L.Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist. Journal of Pharmacology and Experimental Therapeutics 2001, 297(2):688-695.
44. Husbands S.M. Buprenorphine and related orvinols. Research and development of opioid-related ligands 2013, Vol. 1131:127-144. American Chemical Society, Washington, DC.
45. Ignar D.M., Goetz A.S., Noble K.N., Carballo L.H., Stroup A.E., Fisher J.C., et al. Regulation of ingestive behaviors in the rat by GSK1521498, a novel mu-opioid receptor-selective inverse agonist. Journal of Pharmacology and Experimental Therapeutics 2011, 339(1):24-34. 10.1124/jpet.111.180943.
46. Jackson K.J., McLaughlin J.P., Carroll F.I., Damaj M.I. Effects of the kappa opioid receptor antagonist, norbinaltorphimine, on stress and drug-induced reinstatement of nicotine-conditioned place preference in mice. Psychopharmacology 2013, 226(4):763-768. 10.1007/s00213-012-2716-y.
47. Johanson C.E., Fischman M.W. The pharmacology of cocaine related to its abuse. Pharmacological Reviews 1989, 41(1):3-52.
48. Kenakin T. Collateral efficacy in drug discovery: Taking advantage of the good (allosteric) nature of 7TM receptors. Trends in Pharmacological Sciences 2007, 28(8):407-415. 10.1016/j.tips.2007.06.009.
49. Kieffer B.L., Befort K., Gaveriaux-Ruff C., Hirth C.G. The delta-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(24):12048-12052.
50. Kleven M.S., Woolverton W.L. Effects of continuous infusions of SCH 23390 on cocaine- or food-maintained behavior in rhesus monkeys. Behavioural Pharmacology 1990, 1(4):365-373.
51. Koob G.F., Buck C.L., Cohen A., Edwards S., Park P.E., Schlosburg J.E., et al. Addiction as a stress surfeit disorder. Neuropharmacology 2014, 76(Pt B):370-382. 10.1016/j.neuropharm.2013.05.024.
52. Kreek M.J. Medical safety and side effects of methadone in tolerant individuals. JAMA 1973, 223(6):665-668.
53. Kreek M.J. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Annals of New York Academy of Sciences 2000, 909:186-216.
54. Kreek M.J., LaForge K.S., Butelman E. Pharmacotherapy of addictions. Nature Reviews Drug Discovery 2002, 1(9):710-726. 10.1038/nrd897.
55. Kreek M.J., Levran O., Reed B., Schlussman S.D., Zhou Y., Butelman E.R. Opiate addiction and cocaine addiction: Underlying molecular neurobiology and genetics. Journal of Clinical Investigation 2012, 122(10):3387-3393. 10.1172/jci60390.
56. Kuhar M.J., Ritz M.C., Boja J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends in Neurosciences 1991, 14(7):299-302.
57. Kunko P.M., French D., Izenwasser S. Alterations in locomotor activity during chronic cocaine administration: Effect on dopamine receptors and interaction with opioids. Journal of Pharmacology and Experimental Therapeutics 1998, 285(1):277-284.
58. Kuzmin A.V., Gerrits M.A., Zvartau E.E., van Ree J.M. Influence of buprenorphine, butorphanol and nalbuphine on the initiation of intravenous cocaine self-administration in drug naive mice. European Neuropsychopharmacology 2000, 10(6):447-454.
59. Lau E.K., Trester-Zedlitz M., Trinidad J.C., Kotowski S.J., Krutchinsky A.N., Burlingame A.L., et al. Quantitative encoding of the effect of a partial agonist on individual opioid receptors by multisite phosphorylation and threshold detection. Science Signaling 2011, 4(185):ra52. 10.1126/scisignal.2001748.
60. Leri F., Zhou Y., Goddard B., Cummins E., Kreek M.J. Effects of high-dose methadone maintenance on cocaine place conditioning, cocaine self-administration, and mu-opioid receptor mRNA expression in the rat brain. Neuropsychopharmacology 2006, 31(7):1462-1474. 10.1038/sj.npp.1300927.
61. Leri F., Zhou Y., Goddard B., Levy A., Jacklin D., Kreek M.J. Steady-state methadone blocks cocaine seeking and cocaine-induced gene expression alterations in the rat brain. European Neuropsychopharmacology 2009, 19(4):238-249. 10.1016/j.euroneuro.2008.09.004.
62. Ling W., Wesson D.R. Clinical efficacy of buprenorphine: Comparisons to methadone and placebo. Drug and Alcohol Dependence 2003, 70(2 Suppl.):S49-S57.
63. Lutfy K., Eitan S., Bryant C.D., Yang Y.C., Saliminejad N., Walwyn W., et al. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. Journal of Neuroscience 2003, 23(32):10331-10337.
64. Maisonneuve I.M., Ho A., Kreek M.J. Chronic administration of a cocaine "binge" alters basal extracellular levels in male rats: An in vivo microdialysis study. Journal of Pharmacology and Experimental Therapeutics 1995, 272(2):652-657.
65. Martin J.A., Campbell A., Killip T., Kotz M., Krantz M.J., Kreek M.J., et al. QT interval screening in methadone maintenance treatment: Report of a SAMHSA expert panel. Journal of Addictive Diseases 2011, 30(4):283-306. 10.1080/10550887.2011.610710.
66. Mathews J.L., Peng X.M., Xiong W.A., Zhang A., Negus S.S., Neumeyer J.L., et al. Characterization of a novel bivalent morphinan possessing kappa agonist and mu agonist/antagonist properties. Journal of Pharmacology and Experimental Therapeutics 2005, 315(2):821-827. 10.1124/jpet.105.084343.
67. McCance-Katz E.F., Sullivan L.E., Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. American Journal on Addictions 2010, 19(1):4-16. 10.1111/j.1521-0391.2009.00005.x.
68. McCann D.J. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders. Clinical Pharmacology and Therapeutics 2008, 83(4):627-630. 10.1038/sj.clpt.6100503.
69. Mello N.K., Kamien J.B., Lukas S.E., Drieze J., Mendelson J.H. The effects of nalbuphine and butorphanol treatment on cocaine and food self-administration by rhesus monkeys. Neuropsychopharmacology 1993, 8(1):45-55. 10.1038/npp.1993.6.
70. Mello N.K., Lukas S.E., Mendelson J.H., Drieze J. Naltrexone-buprenorphine interactions: Effects on cocaine self-administration. Neuropsychopharmacology 1993, 9(3):211-224. 10.1038/npp.1993.57.
71. Mello N.K., Negus S.S. Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 1998, 286(2):812-824.
72. Mello N.K., Negus S.S. Interactions between kappa opioid agonists and cocaine. Preclinical studies. Annals of New York Academy of Sciences 2000, 909:104-132.
73. Mendelson J.H., Mello N.K. Management of cocaine abuse and dependence. New England Journal of Medicine 1996, 334(15):965-972. 10.1056/nejm199604113341507.
74. Montoya I.D., Gorelick D.A., Preston K.L., Schroeder J.R., Umbricht A., Cheskin L.J., et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clinical Pharmacology and Therapeutics 2004, 75(1):34-48. 10.1016/j.clpt.2003.09.004.
75. Mooney L.J., Nielsen S., Saxon A., Hillhouse M., Thomas C., Hasson A., et al. Cocaine use reduction with buprenorphine (CURB): Rationale, design, and methodology. Contemporary Clinical Trials 2013, 34(2):196-204. 10.1016/j.cct.2012.11.002.
76. Murnane K.S., Winschel J., Schmidt K.T., Stewart L.M., Rose S.J., Cheng K., et al. Serotonin 2A receptors differentially contribute to abuse-related effects of cocaine and cocaine-induced nigrostriatal and mesolimbic dopamine overflow in nonhuman primates. Journal of Neuroscience 2013, 33(33):13367-13374. 10.1523/jneurosci.1437-13.2013.
77. Negus S.S., Bidlack J.M., Mello N.K., Furness M.S., Rice K.C., Brandt M.R. Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behavioural Pharmacology 2002, 13(7):557-570.
78. Negus S.S., Mello N.K. Effects of mu-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: Role of mu-agonist efficacy. Journal of Pharmacology and Experimental Therapeutics 2002, 300(3):1111-1121.
79. Negus S.S., Mello N.K., Lamas X., Mendelson J.H. Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 1996, 278(2):879-890.
80. Negus S.S., Mello N.K., Portoghese P.S., Lin C.E. Effects of kappa opioids on cocaine self-administration by rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 1997, 282(1):44-55.
81. Neumeyer J.L., Bidlack J.M., Zong R.S., Bakthavachalam V., Gao P., Cohen D.J., et al. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence. Journal of Medicinal Chemistry 2000, 43(1):114-122. 10.1021/jm9903343.
82. Neumeyer J.L., Zhang B., Zhang T.Z., Sromek A.W., Knapp B.I., Cohen D.J., et al. Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors. Journal of Medicinal Chemistry 2012, 55(8):3878-3890. 10.1021/jm3001086.
83. Nutt D.J. Antagonist-agonist combinations as therapies for heroin addiction: Back to the future?. Journal of Psychopharmacology 2010, 24(2):141-145. 10.1177/0269881109356129.
84. Patkar K.A., Murray T.F., Aldrich J.V. The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. Journal of Medicinal Chemistry 2009, 52(21):6814-6821. 10.1021/jm900715m.
85. Patkar K.A., Wu J., Ganno M.L., Singh H.D., Ross N.C., Rasakham K., et al. Physical presence of nor-binaltorphimine in mouse brain over 21 days after a single administration corresponds to its long-lasting antagonistic effect on kappa-opioid receptors. Journal of Pharmacology and Experimental Therapeutics 2013, 346(3):545-554. 10.1124/jpet.113.206086.
86. 2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist. Journal of Medicinal Chemistry 2005, 48(14):4500-4503. 10.1021/jm050105i.
87. Peles E., Kreek M.J., Kellogg S., Adelson M. High methadone dose significantly reduces cocaine use in methadone maintenance treatment (MMT) patients. Journal of Addictive Diseases 2006, 25(1):43-50. 10.1300/J069v25n01_07.
88. Pettinati H.M., Kampman K.M., Lynch K.G., Suh J.J., Dackis C.A., Oslin D.W., et al. Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. Journal of Substance Abuse Treatment 2008, 34(4):378-390. 10.1016/j.jsat.2007.05.011.
89. Pettit H.O., Ettenberg A., Bloom F.E., Koob G.F. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology 1984, 84(2):167-173.
90. Picetti R., Schlussman S.D., Zhou Y., Ray B., Ducat E., Yuferov V., et al. Addictions and stress: Clues for cocaine pharmacotherapies. Current Pharmaceutical Design 2013, 19:7065-7080. PMID: 23574443.
91. Pickworth W.B., Lee E.M., Abreu M.E., Umbricht A., Preston K.L. A laboratory study of hydromorphone and cyclazocine on smoking behavior in residential polydrug users. Pharmacology Biochemistry and Behavior 2004, 77(4):711-715. 10.1016/j.pbb.2004.01.022.
92. Preston K.L., Urnbricht A., Schroeder J.R., Abreu M.E., Epstein D.H., Pickworth W.B. Cyclazocine: Comparison to hydromorphone and interaction with cocaine. Behavioural Pharmacology 2004, 15(2):91-102. 10.1097/01.fbp.0000125793.85076.47.
93. Provencher B.A., Sromek A., Li W., Russell S., Chartoff E., Knapp B.I., et al. Synthesis and pharmacological evaluation of mixed mu/kappa aminothiazolomorphinans. Journal of Medicinal Chemistry 2013, 56:8872-8878.
94. Redila V.A., Chavkin C. Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. Psychopharmacology (Berlin) 2008, 200(1):59-70. 10.1007/s00213-008-1122-y.
95. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987, 237(4819):1219-1223.
96. Ross N.C., Kulkarni S.S., McLaughlin J.P., Aldrich J.V. Synthesis of CJ-15,208, a novel kappa-opioid receptor antagonist. Tetrahedron Letters 2010, 51(38):5020-5023. 10.1016/j.tetlet.2010.07.086.
97. Ross N.C., Reilley K.J., Murray T.F., Aldrich J.V., McLaughlin J.P. Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting kappa opioid receptor antagonism. British Journal of Pharmacology 2012, 165(4b):1097-1108. 10.1111/j.1476-5381.2011.01544.x.
98. Rothman R.B., Gorelick D.A., Heishman S.J., Eichmiller P.R., Hill B.H., Norbeck J., et al. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. Journal of Substance Abuse Treatment 2000, 18(3):277-281.
99. Ruedi-Bettschen D., Rowlett J.K., Spealman R.D., Platt D.M. Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys: Kappa opioid and serotonergic mechanisms. Psychopharmacology 2010, 210(2):169-177. 10.1007/s00213-009-1705-2.
100. Saito T., Hirai H., Kim Y.J., Kojima Y., Matsunaga Y., Nishida H., et al. CJ-15,208, a novel kappa opioid receptor antagonist from a fungus, Ctenomyces serratus ATCC15502. The Journal of Antibiotics (Tokyo) 2002, 55(10):847-854.
101. Schattauer S.S., Miyatake M., Shankar H., Zietz C., Levin J.R., Liu-Chen L.Y., et al. Ligand directed signaling differences between rodent and human kappa-opioid receptors. Journal of Biological Chemistry 2012, 287(50):41595-41607. 10.1074/jbc.M112.381368.
102. Schindler A.G., Messinger D.I., Smith J.S., Shankar H., Gustin R.M., Schattauer S.S., et al. Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake. Journal of Neuroscience 2012, 32(49):17582-17596. 10.1523/jneurosci.3220-12.2012.
103. Selley D.E., Sim L.J., Xiao R., Liu Q., Childers S.R. mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: Signal transduction mechanisms underlying agonist efficacy. Molecular Pharmacology 1997, 51(1):87-96.
104. Shippenberg T.S., Zapata A., Chefer V.I. Dynorphin and the pathophysiology of drug addiction. Pharmacology & Therapeutics 2007, 116(2):306-321. 10.1016/j.pharmthera.2007.06.011.
105. 35S]thio]-triphosphate binding. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(16):7242-7246.
106. Simonin F., Befort K., Gaveriaux-Ruff C., Matthes H., Nappey V., Lannes B., et al. The human delta-opioid receptor: Genomic organization, cDNA cloning, functional expression, and distribution in human brain. Molecular Pharmacology 1994, 46(6):1015-1021.
107. Smith M.A., Cole K.T., Iordanou J.C., Kerns D.C., Newsom P.C., Peitz G.W., et al. The mu/kappa agonist nalbuphine attenuates sensitization to the behavioral effects of cocaine. Pharmacology Biochemistry and Behavior 2013, 104:40-46. 10.1016/j.pbb.2012.12.026.
108. Smith M.A., Gordon K.A., Craig C.K., Bryant P.A., Ferguson M.E., French A.M., et al. Interactions between opioids and cocaine on locomotor activity in rats: Influence of an opioid's relative efficacy at the mu receptor. Psychopharmacology 2003, 167(3):265-273. 10.1007/s00213-003-1388-z.
109. Sofuoglu M., Singha A., Kosten T.R., McCance-Katz F.E., Petrakis I., Oliveto A. Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. Pharmacology Biochemistry and Behavior 2003, 75(4):801-808.
110. Sorge R.E., Stewart J. The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration. Psychopharmacology 2006, 188(1):28-41. 10.1007/s00213-006-0485-1.
111. Soyka M., Rosner S. Opioid antagonists for pharmacological treatment of alcohol dependence-A critical review. Current Drug Abuse Reviews 2008, 1(3):280-291.
112. Spagnolo B., Calo G., Polgar W.E., Jiang F., Olsen C.M., Berzetei-Gurske I., et al. Activities of mixed NOP and mu-opioid receptor ligands. British Journal of Pharmacology 2008, 153(3):609-619. 10.1038/sj.bjp.0707598.
113. Spanagel R., Herz A., Shippenberg T.S. The effects of opioid peptides on dopamine release in the nucleus accumbens: An in vivo microdialysis study. Journal of Neurochemistry 1990, 55(5):1734-1740.
114. Spangler R., Unterwald E.M., Kreek M.J. 'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Brain Research. Molecular Brain Research 1993, 19(4):323-327.
115. Stevenson G.W., Wentland M.P., Bidlack J.M., Mello N.K., Negus S.S. Effects of the mixed-action kappa/mu opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys. European Journal of Pharmacology 2004, 506(2):133-141. 10.1016/j.ejphar.2004.10.051.
116. Sullivan M.A., Bisaga A., Mariani J.J., Glass A., Levin F.R., Comer S.D., et al. Naltrexone treatment for opioid dependence: Does its effectiveness depend on testing the blockade?. Drug and Alcohol Dependence 2013, 133:80-85. 10.1016/j.drugalcdep.2013.05.030.
117. Toll L., Khroyan T.V., Polgar W.E., Husbands S.M., Zaveri N.T. Pharmacology of mixed NOP/Mu ligands. Research and Development of Opioid-Related Ligands 2013, 1131:369-391. American Chemical Society.
118. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Molecular Pharmacology 1995, 47(4):848-854.
119. Violin J.D., Lefkowitz R.J. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends in Pharmacological Sciences 2007, 28(8):416-422. 10.1016/j.tips.2007.06.006.
120. Walsh S.L., Geter-Douglas B., Strain E.C., Bigelow G.E. Enadoline and butorphanol: Evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. Journal of Pharmacology and Experimental Therapeutics 2001, 299(1):147-158.
121. Wang J.B., Johnson P.S., Persico A.M., Hawkins A.L., Griffin C.A., Uhl G.R. Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Letters 1994, 338(2):217-222.
122. Wang Y.J., Tao Y.M., Li F.Y., Wang Y.H., Xu X.J., Chen J., et al. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior. Journal of Pharmacology and Experimental Therapeutics 2009, 329(1):306-313. 10.1124/jpet.108.142802.
123. Wee S., Koob G.F. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology 2010, 210(2):121-135. 10.1007/s00213-010-1825-8.
124. Wee S., Orio L., Ghirmai S., Cashman J.R., Koob G.F. Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine. Psychopharmacology (Berlin) 2009, 205(4):565-575. 10.1007/s00213-009-1563-y.
125. Wee S., Vendruscolo L.F., Misra K.K., Schlosburg J.E., Koob G.F. A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence. Science Translational Medicine 2012, 4(146):146ra110. 10.1126/scitranslmed.3003948.
126. Wentland M.P., Lou R.L., Dehnhardt C.M., Duan W.H., Cohen D.J., Bidlack J.M. 3-Carboxamido analogues of morphine and naltrexone: Synthesis and opioid receptor binding properties. Bioorganic & Medicinal Chemistry Letters 2001, 11(13):1717-1721. 10.1016/s0960-894x(01)00278-5.
127. Wentland M.P., Lou R., Lu Q., Bu Y., Denhardt C., Jin J., et al. Syntheses of novel high affinity ligands for opioid receptors. Bioorganic & Medicinal Chemistry Letters 2009, 19(8):2289-2294. 10.1016/j.bmcl.2009.02.078.
128. Wentland M.P., Lou R., Lu Q., Bu Y., VanAlstine M.A., Cohen D.J., et al. Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorganic & Medicinal Chemistry Letters 2009, 19(1):203-208. 10.1016/j.bmcl.2008.10.134.
129. Wentland M.P., Lou R.L., Ye Y.C., Cohen D.J., Richardson G.P., Bidlack J.M. 8-Carboxamidocyclazocine analogues: Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Bioorganic & Medicinal Chemistry Letters 2001, 11(5):623-626. 10.1016/s0960-894x(01)00014-2.
130. Wentland M.P., Lu Q., Lou R.L., Bu Y.G., Knapp B.I., Bidlack J.M. Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone. Bioorganic & Medicinal Chemistry Letters 2005, 15(8):2107-2110. 10.1016/j.bmcl.2005.02.032.
131. Wentland M.P., VanAlstine M., Kucejko R., Lou R.L., Cohen D.J., Parkhill A.L., et al. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 4. Opioid receptor binding properties of 8- N-(4'-phenyl)-phenethyl)carboxamido analogues of cyclazocine and ethylketocycalzocine. Journal of Medicinal Chemistry 2006, 49(18):5635-5639. 10.1021/jm060278n.
132. Zhang Y., Schlussman S.D., Rabkin J., Butelman E.R., Ho A., Kreek M.J. Chronic escalating cocaine exposure, abstinence/withdrawal, and chronic re-exposure: Effects on striatal dopamine and opioid systems in C57BL/6J mice. Neuropharmacology 2013, 67:259-266. 10.1016/j.neuropharm.2012.10.015.
133. Zhang A., Xiong W.N., Bidlack J.M., Hilbert J.E., Knapp B.I., Wentland M.P., et al. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and mu opioid ligands: Synthesis and biological evaluation of their binding affinity at opioid receptors. Journal of Medicinal Chemistry 2004, 47(1):165-174. 10.1021/jm0304156.
134. Zhang A., Xiong W.N., Hilbert J.E., DeVita E.K., Bidlack J.M., Neumeyer J.L. 2-Aminothiazole-derived opioids. Bioisosteric replacement of phenols. Journal of Medicinal Chemistry 2004, 47(8):1886-1888. 10.1021/jm049978n.
135. Zhang T.Z., Yan Z.H., Sromek A., Knapp B.I., Scrimale T., Bidlack J.M., et al. Aminothiazolomorphinans with mixed kappa and mu opioid activity. Journal of Medicinal Chemistry 2011, 54(6):1903-1913. 10.1021/jm101542c.
136. Zhu J., Chen C., Xue J.C., Kunapuli S., DeRiel J.K., Liu-Chen L.Y. Cloning of a human kappa opioid receptor from the brain. Life Sciences 1995, 56(9):l201-l207.